PSY89 Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute  by Rule, S. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A537
5Centro Aziendale di Ematologia, Livorno, Italy, 6University Hospital Giessen and Marburg, 
Giessen, Germany
Objectives: Rituximab SC reduces administration times (~5 minutes) com-
pared with the IV route (~4 hours). We examined the extent of patient prefer-
ence for rituximab SC versus IV in the PrefMab and MabCute studies using the 
Rituximab Administration Satisfaction Questionnaire (RASQ). MethOds: In 
PrefMab (NCT01724021) patients with untreated CD20+ DLBCL/FL received 1 cycle 
of IV rituximab (375mg/m2) followed by either SC rituximab (1400mg, x3) then IV 
rituximab (x4), or IV rituximab (x3) then SC rituximab (x4), with chemotherapy. 
In MabCute (NCT01461928) patients with relapsed/refractory CD20+ indolent NHL 
received induction rituximab IV (375mg/m2; 1 cycle) then rituximab SC (1400mg; 
cycles 2–8) plus 6–8 chemotherapy cycles. RASQ evaluated preference by assessing 
patients’ perceptions of the impact of administration route and treatment satisfac-
tion. Conceptual validation of RASQ has been conducted and psychometric data 
will be reported. Results: Median RASQ scores for PrefMab were: convenience IV 
(n= 211) 58.3 (interquartile range: 41.7–75.0) and SC (n= 207) 83.3 (75.0–91.7); satisfac-
tion: IV (n= 211) 75.0 (62.5–87.5), SC (n= 208) 87.5 (75.0–100.0); impact on daily life: 
IV (n= 145) 50.0 (41.7–83.3), SC (n= 163) 83.3 (83.3–100.0); physical impact IV (n= 211) 
83.3 (66.7–100.0), SC (n= 208) 83.3 (75.0–100.0); psychological impact IV (n= 211) 80.0 
(65.0–90.0), SC (n= 208) 88.8 (75.0–95.0). SC administration was preferred by 80.3% 
and 85.9% of patients with IV or SC as most recent dose, respectively. Results were 
similar irrespective of treatment sequence. Median RASQ scores for MabCute 
(n= 92) were: convenience: IV 58.3 (33.3–66.7), SC 83.3 (66.7–83.3); satisfaction: IV 
62.5 (50.0–87.5), SC 87.5 (75.0–100.0); impact on daily life: IV 58.3 (41.7–66.7), SC 83.3 
(66.7–83.3); physical impact IV 75.0 (66.7–91.7), SC 83.3 (66.7–91.7); psychological 
impact IV 70.0 (60.0–85.0), SC 85.0 (75.0–95.0). cOnclusiOns: Consistent patient 
satisfaction and preference for SC versus IV rituximab was demonstrated in the 
PrefMab and MabCute studies. RASQ is a reliable and valid measure of patient treat-
ment preference.
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Objectives: We conducted a systematic literature review to identify published 
evidence from observational studies on the humanistic burden of multiple myeloma 
(MM). MethOds: We searched MEDLINE, Embase, EconLit, and the Cochrane Library 
for English-language articles and analysed these qualitatively. Results: The review 
identified 20 publications based on 18 observational studies; these were mainly 
cross-sectional in design (n= 14). Most studies (n= 15) examined populations with 
MM in general, typically without stating the proportion with relapsed (R) or relapsed 
and refractory (RR) MM. Fewer studies examined patients with newly-diagnosed 
MM (n= 2) or RMM/RRMM (n= 1). Health-related quality of life (HRQoL) was typically 
assessed using validated cancer-specific instruments (e. g., the EORTC-QLQ-C30: 
n= 9; and the MM-specific EORTC-QLQ-MY20: n= 4). On average, patients with MM 
had poorer HRQoL compared to the general population (n= 6), and compared to 
patients with certain other hematologic cancers (n= 2). MM patients whose disease 
duration ranged from diagnosis to 11 years had greater physical function impair-
ment (p< 0.001) than other hematologic cancer patients. Other complaints included 
fatigue, bone pain, tingling, and non-specific pain. Patients on active treatment had 
worse side effects than those in a first treatment-free interval (p< 0.001); the latter 
had better scores on HRQoL dimensions including role and social function, future 
perspectives, and body image (all p< 0.05). Between baseline and one year, patients 
experienced worsening on the EORTC-QLQ-C30 global health scale (p< 0.001) and 
in fatigue, nausea/vomiting, and pain scores (all p< 0.05). Symptomatic patients 
had lower physical functioning scores (p< 0.05) than asymptomatic patients; those 
with severe symptoms had lower EORTC-QLQ-C30 global health scores (p< 0.05; 
mild/moderate symptoms: p= NS). Fatigue, bone pain, and anaemia were associated 
with lower. cOnclusiOns: HRQoL in patients with MM deteriorates with disease 
duration, symptom severity, disease progression, or development of complications. 
This evidence suggests substantial unmet needs in MM patients.
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Objectives: There are approximately 2,000 hemophilia patients in Korea, but 
patient-reported outcome (PRO) studies involving a large number of hemophilia 
patients have been rarely studied. The aim of this study was to assess PROs in 
moderate to severe hemophilia patients in Korea. MethOds: It was a cross- 
sectional, multi-centered and observational study. Moderate to severe, male 
hemophilia patients aged 8 to 65 were recruited at 2 of Korea Hemophilia 
Foundations and 3 other pediatrics from November 2012 to September 2013. 
All patients completed self-reported questionnaires to measure patients’ char-
acteristics and PROs including health-related quality of life (HRQoL) and pro-
ductivity loss. HRQoL was examined using EQ-5D, ranged 0-1, which higher 
values indicate better HRQoL and Heamo-QoL, ranged 0-100, where higher val-
ues imply lower HRQoL. Productivity loss was estimated with absenteeism and 
presentism in terms of lost productivity time (LPT). Results: For a total of 605 
patients (mean age, 29.3 years; 88.6% with severe hemophilia) enrolled in this 
study, the mean scores of heamo-QoL and EQ-5D were 32.28 and 0.68 respec-
tively. The mean scores of EQ-5D in this study are comparable to 0.68 in rheu-
matoid arthritis patients from Korea Observational Study Network for Arthritis. 
Significantly lower EQ-5D was found in patients with the following clinical factors 
compared to those with reverse conditions; joint bleedings (0.68 vs. 0.73, p= .001), 
in platelet count. During recovery phase WBC count increased first followed by plate-
lets count production after 3-4 days. Among 1000 confirmed dengue fever patients 
812 were considered dengue hemorrhagic fever cases on the basis of clinical finding. 
In most of these cases (n= 783; 96.47%), directly proportional relation was observed 
between WBC and platelets count. cOnclusiOns: It is wrongly perceived in com-
munity that dengue virus infection is still progressing when platelets count is below 
normal even the white blood cells counts is getting better during recovery phase. 
White blood cells production during recovery phase is a good indicator about recov-
ery of disease rather than focused on platelets counts production.
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Objectives: To define the importance values assigned to the attributes of bio-
logical agents (BA) by Spanish rheumatologists and patients with rheumatic dis-
eases: rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis 
(PA). MethOds: Observational, cross-sectional design based on conjoint analy-
sis. RA, AS and PA patients diagnosed at least 2 years prior and currently or pre-
viously (≤ 1 year ago) receiving BA for a minimum of 1 year were consecutively 
recruited. Rheumatologists with at least 3 year experience on BAs participated. A 
literature review and 4 focus groups were undertaken to identify attributes and 
levels. Scenarios were selected using orthogonal design. Participants ranked 8 
scenarios from 1 (most preferred) to 8 (least preferred). Relative importance (RI) 
of attributes was calculated. Multivariate regression analysis was performed for 
each attribute. Results: 488 patients [male= 50.9%; mean (SD) age= 50.6 (12.06) 
years; RA= 33.8%, AS= 32.4%, PA= 33.8%; mean time from diagnosis= 12.6 (8.2) years] 
and 136 rheumatologists [male= 50.4%; mean age= 46.4 (9.1) years; mean time of 
practice= 16.7 (8.8) years] took part. Most important attributes selected by patients 
and physicians, respectively, were: ‘Pain relief and improvement of the functional 
capacity’ (RI= 49.1% and 48.9%); ‘Risk of adverse events’ (RI= 31.8% and 31.5%), 
‘Administration method’ (RI= 10.2% and 11.4%) and ‘Time to perceive the need for 
a new dose’ (RI= 9.0% and 8.2%). The ideal BA, for patients and physicians, should 
allow pain relief and an improvement of the functional capacity, with a low risk 
of adverse events, a long time prior to perceiving the need for a new dose and 
self-administration at home, when possible. cOnclusiOns: Although efficacy and 
safety are key for patients with rheumatic diseases and rheumatologists to make a 
choice over a BA, the need for a low frequency of administration and the administra-
tion method also play an important role as preference attributes for BAs in Spain.
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Objectives: Biological agents (BA) to treat rheumatic diseases are commonly 
administered by either the subcutaneous or the intravenous route. The objective 
of this study was to assess rheumatoid arthritis (RA), ankylosing spondylitis (AS) 
and psoriatic arthritis (PA) Spanish patients’ preferences over BA considering the 
administration route. MethOds: Observational, cross-sectional design. Participants 
were RA, AS and PA patients (diagnosed ≥ 2 years prior to study entry; currently 
or previously (≤ 1 year ago) receiving BA for a minimum of 1 year. Conjoint analy-
sis was performed to define preferences over 8 scenarios combining 4 attributes 
[‘Administration method’ (ADMINISTRATION), ‘Pain relief and improvement of the 
functional capacity’ (RELIEF), ‘Risk of adverse events’ (AE) and ‘Time until perceiv-
ing the need for a new dose’ related to the frequency of administration (TIME)]. 
Relative importance (RI) was calculated for patients on subcutaneous or intravenous 
administration, respectively. Results: A total of 488 patients [male= 50.9%; mean 
(SD) age= 50.6 (12.06) years; RA= 33.8%, AS= 32.4%, PA= 33.8%; mean time from diag-
nosis= 12.6 (8.2) years; receiving currently BA= 98.2%] were included. The patients 
currently receiving subcutaneous (n= 305) or intravenous (n= 174) administration 
with BA gave highest importance to ‘RELIEF’ (45.4% and 46.7%) and ‘AE’ (28.2% and 
31.8%), followed by ‘ADMINISTRATION’ (19.7% and 10.2%) and ‘TIME’ (6.7% and 11.3%, 
respectively). Both groups of patients preferred to stay on the same route of adminis-
tration, either subcutaneous or intravenous, they had been on. Moreover all patients 
considered most crucial a longer time until perceiving the need for a new dose (8 
over 4 over 2 over 1 week). cOnclusiOns: Spanish patients with rheumatic dis-
eases placed high importance on pain relief and risk of AEs as preference attributes 
for BAs. The frequency of administration (time until perceiving the need for a new 
dose) also plays a crucial role as all patients indicated their preference for lower vs. 
higher frequencies of BA administration.
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